Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients

Review of Diabetic Studies

Volumn 10, Issue 2-3, 2013, Pages 213-222

  Chang, Yu Hung ^a   Lin, Kun Cheng ^a   Chang, Dao Ming ^a   Hsieh, Chang Hsun ^b   Lee, Yau Jiunn ^a  

^a Lee's Endocrinologic Clinic   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Atorvastatin; High density lipoprotein cholesterol; Lipid; Simvastatin; Type 2 diabetes

Indexed keywords

ATORVASTATIN; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHINA; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN; TAIWAN; TRIGLYCERIDES;

EID: 84891804252     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2013.10.213     Document Type: Article

References (37)

1. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of followup. Arch Intern Med 2004. 164:1422-1426.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005. 352:1685-1695.
3. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997. 20:614-620.
4. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003. 361:2005-2016.
5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004. 364:685-696.
6. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial lipidlowering arm (ASCOT-LLA). Diabetes Care 2005. 28:1151-1157.
7. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006. 29:1220-1226.
8. American Diabetes Association. Standards of medical care in diabetes 2012. Diabetes Care 2012. 35(Suppl 1):S11-S63.
9. Chapman J. Beyound LDL-cholesterol reduction: the way ahead in managing dyslipidaemia. Eur Heart J Suppl 2005. 7:F56-F62.
10. Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled lowdensity lipoprotein cholesterol. Am J Cardiol 2007. 100:1499-1501.
11. Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med 2007. 24:388-391.
12. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979. 90:85-91.
13. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001. 101:671-679.
14. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Holman RR. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002. 33:1776-1781.
15. Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med 2010. 153:800-808.
16. McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther 2008. 22:321-338.
17. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis AB, Tipping D, Tomassini JE, Tershakovec AM. Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. Diabetes Care 2010. 33:1021-1024.
18. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008. 64:877-882.
19. Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol 2011. 51:181-188.
20. Kolovou G, Kolovou V, Mihas C, Giannakopoulou V, Vasiliadis I, Boussoula E, Kollia A, Boutsikou M, Katsiki N, Mavrogeni S. Cholesteryl Ester Transfer Protein and ATP-Binding Cassette Transporter A1 Genotype Alter the Atorvastatin and Simvastatin Efficacy: Time for Genotype-Guided Therapy? Angiology 2012. In press.
21. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011. 27:515-527.
22. Chang YH, Chang DM, Lin KC, Hsieh CH, Lee YJ. High-density lipoprotein cholesterol and the risk of nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2013. 23:751-757.
23. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population. Rev Diabet Stud 2006. 3:21-30.
24. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010. 56:977-986.
25. Karlson BW, Barter PJ, Palmer MK, Lundman P, Nicholls SJ. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutr Metab Cardiovasc Dis 2012. 22:697-703.
26. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006. 29:1478-1485.
27. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003. 33:1051-1069.
28. Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004. 24:1755-1760.
29. Chu CH, Lee JK, Lam HC, Lu CC, Sun CC, Wang MC, Chuang MJ, Wei MC. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest 2008. 31:42-47.
30. Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with type 2 diabetes mellitus. Diabet Med 2011. 28:856-864.
31. Akalin A, Temiz G, Akcar N, Sensoy B. Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocr J 2008. 55:861-866.
32. Rogers SL, Magliano DJ, Levison DB, Webb K, Clarke PJ, Grobler MP, Liew D. A dose-specific metaanalysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. Clin Ther 2007. 29:242-252.
33. Arnaboldi L, Corsini A. Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol 2010. 21:298-304.
34. Huang Y, Wu Y, Liu R, Fan P, Zhang J, Wang F, Luo X, Liu Y, Liu B, Bai H. Differential effect of ATP binding cassette transporter A1 R219K and cholesteryl ester transfer protein TaqIB genotypes on HDL-C levels in overweight/obese and non-obese Chinese subjects. Acta cardiologica 2011. 66:231-237.
35. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010. 362:1563-1574.
36. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006. 17:631-636.
37. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011. 365:2255-2267.